- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00005364
Genetic Epidemiology of CHD Risk Factors in Blacks
연구 개요
상세 설명
DESIGN NARRATIVE:
The study used two well defined African populations from Nigeria to determine the contribution of 14 polymorphic genes involved in lipid metabolism in determining quantitative lipoprotein-lipid and apolipoprotein levels as these are major risk factors for coronary heart disease. The study also investigated how differences in life styles and dietary habits modulate the genetic contribution of these quantitative risk factors. Phenotypes in the gene products of APOs A-IV, C-II, D, H, J and (a) were determined by IEF and SDS/immunoblotting. Genotypes at the B,E, AI-CIII- AIV cluster, lipoprotein lipase, hepatic lipase, LDL-receptor, and cholesterol ester transfer protein were determined by polymerase chain reaction protocols. The quantitative levels of total cholesterol, HDL-cholesterol and its subfractions, HDL2- and HDL3-cholesterol, triglycerides and LP(a) were used in the genetic analyses. Estimates of the effect of alleles at each of the candidate loci on quantitative lipoprotein-lipid levels employed the measured genotype approach. The effect of multisite haplotypes for RFLP at various loci, where applicable, was also estimated using the same method. The interaction of alleles at various independent loci in determining quantitative lipoprotein-lipid and apolipoprotein levels was estimated. In addition to the measurements of environmental effects, measurements were also made of the genotype-environmental interaction in determining quantitative risk factor traits.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
연구 유형
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
공부 계획
연구는 어떻게 설계됩니까?
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Evans RW, Sankey SS, Hauth BA, Sutton-Tyrrell K, Kamboh MI, Kuller LH. Effect of sample storage on quantitation of lipoprotein(a) by an enzyme-linked immunosorbent assay. Lipids. 1996 Nov;31(11):1197-203. doi: 10.1007/BF02524295.
- Islam S, Gutin B, Smith C, Treiber F, Kamboh MI. Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease. Arterioscler Thromb. 1994 Oct;14(10):1609-16. doi: 10.1161/01.atv.14.10.1609.
- Anderson JL, Bunker CH, Aston CE, Kamboh MI. Relationship of two apolipoprotein B polymorphisms with serum lipoprotein and lipid levels in African blacks. Hum Biol. 1997 Dec;69(6):793-807.
- Saha N, Wang G, Vasisht S, Kamboh MI. Influence of two apo A4 polymorphisms at codons 347 and 360 on non-fasting plasma lipoprotein-lipids and apolipoproteins in Asian Indians. Atherosclerosis. 1997 Jun;131(2):249-55. doi: 10.1016/s0021-9150(97)06112-1.
- Kamboh MI, Sanghera DK, Aston CE, Bunker CH, Hamman RF, Ferrell RE, DeKosky ST. Gender-specific nonrandom association between the alpha 1-antichymotrypsin and apolipoprotein E polymorphisms in the general population and its implication for the risk of Alzheimer's disease. Genet Epidemiol. 1997;14(2):169-80. doi: 10.1002/(SICI)1098-2272(1997)14:23.0.CO;2-2.
- Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1067-73. doi: 10.1161/01.atv.17.6.1067.
- Harris M, Sanghera DK, Kamboh MI. Short report on DNA marker at candidate locus. Two new alleles in the tetranucleotide repeat polymorphism in the LDL-receptor-related protein (LRP) gene. Clin Genet. 1996 Jul;50(1):54-5. No abstract available.
- Kamboh MI, Evans RW, Aston CE. Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease in American black women. Atherosclerosis. 1995 Sep;117(1):73-81. doi: 10.1016/0021-9150(95)05559-f.
- Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis. 1995 Jan 20;112(2):145-59. doi: 10.1016/0021-9150(94)05409-c.
- Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 1998 Jan;62(1):36-44. doi: 10.1086/301669.
- Sanghera DK, Saha N, Kamboh MI. The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis. 1998 Feb;136(2):217-23. doi: 10.1016/s0021-9150(97)00206-2.
- Ali S, Bunker CH, Aston CE, Ukoli FA, Kamboh MI. Apolipoprotein A kringle 4 polymorphism and serum lipoprotein (a) concentrations in African blacks. Hum Biol. 1998 Jun;70(3):477-90.
- Harris MR, Bunker CH, Hamman RF, Sanghera DK, Aston CE, Kamboh MI. Racial differences in the distribution of a low density lipoprotein receptor-related protein (LRP) polymorphism and its association with serum lipoprotein, lipid and apolipoprotein levels. Atherosclerosis. 1998 Mar;137(1):187-95. doi: 10.1016/s0021-9150(97)00230-x.
- Nestlerode CS, Bunker CH, Sanghera DK, Aston CE, Ukoli FA, Kamboh MI. Apolipoprotein J polymorphisms and serum HDL cholesterol levels in African blacks. Hum Biol. 1999 Apr;71(2):197-218.
- Kamboh MI, Bunker CH, Aston CE, Nestlerode CS, McAllister AE, Ukoli FA. Genetic association of five apolipoprotein polymorphisms with serum lipoprotein-lipid levels in African blacks. Genet Epidemiol. 1999;16(2):205-22. doi: 10.1002/(SICI)1098-2272(1999)16:23.0.CO;2-P.
- Kamboh MI. Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease. Hum Biol. 1995 Apr;67(2):195-215.
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심장 질환에 대한 임상 시험
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University of... 그리고 다른 협력자들아직 모집하지 않음심부전, 수축기 | 박출률이 감소된 심부전 | 심부전 New York Heart Association Class IV | 심부전 New York Heart Association Class III폴란드
-
Novartis Pharmaceuticals완전한핵심 연구의 12개월 치료 기간을 성공적으로 완료한 환자(de Novo Heart Recipients)는 EC-MPS 치료에 관심이 있었습니다.
-
University of WashingtonAmerican Heart Association완전한심부전,울혈 | 미토콘드리아 변경 | 심부전 New York Heart Association Class IV미국
-
University of Pennsylvania완전한Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410의 주진단 또는 이차진단 코드가 있는 환자(5번째 숫자가 2인 경우 제외)미국